These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 9209471)
61. The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells. Peruzzi B; Athauda G; Bottaro DP Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14531-6. PubMed ID: 16983094 [TBL] [Abstract][Full Text] [Related]
62. Von Hippel-Lindau disease and sporadic renal cell carcinoma. Zbar B Cancer Surv; 1995; 25():219-32. PubMed ID: 8718521 [TBL] [Abstract][Full Text] [Related]
63. VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism. An J; Fisher M; Rettig MB Oncogene; 2005 Feb; 24(9):1563-70. PubMed ID: 15608669 [TBL] [Abstract][Full Text] [Related]
64. Clear cell papillary renal cell carcinoma-like tumors in patients with von Hippel-Lindau disease are unrelated to sporadic clear cell papillary renal cell carcinoma. Williamson SR; Zhang S; Eble JN; Grignon DJ; Martignoni G; Brunelli M; Wang M; Gobbo S; Baldridge LA; Cheng L Am J Surg Pathol; 2013 Aug; 37(8):1131-9. PubMed ID: 23648463 [TBL] [Abstract][Full Text] [Related]
65. Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Maranchie JK; Afonso A; Albert PS; Kalyandrug S; Phillips JL; Zhou S; Peterson J; Ghadimi BM; Hurley K; Riss J; Vasselli JR; Ried T; Zbar B; Choyke P; Walther MM; Klausner RD; Linehan WM Hum Mutat; 2004 Jan; 23(1):40-6. PubMed ID: 14695531 [TBL] [Abstract][Full Text] [Related]
66. Loss of heterozygosity on 3p in a renal cell carcinoma in von Hippel-Lindau syndrome. Decker HJ; Gemmill RM; Neumann HP; Walter TA; Sandberg AA Cancer Genet Cytogenet; 1989 Jun; 39(2):289-93. PubMed ID: 2568884 [TBL] [Abstract][Full Text] [Related]
68. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766 [TBL] [Abstract][Full Text] [Related]
69. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma. Igarashi H; Esumi M; Ishida H; Okada K Cancer; 2002 Jul; 95(1):47-53. PubMed ID: 12115316 [TBL] [Abstract][Full Text] [Related]
70. Establishment of experimental conditions for the rapid detection of mutations in the von Hippel-Lindau gene by parallel temperature gradient gel electrophoresis. Hernández A; Meyer A; Enczmann J; Ackermann R; Wernet P Electrophoresis; 1999 Jul; 20(10):1958-61. PubMed ID: 10451103 [TBL] [Abstract][Full Text] [Related]
71. Involvement of multiple loci on chromosome 3 in renal cell cancer development. van den Berg A; Buys CH Genes Chromosomes Cancer; 1997 Jun; 19(2):59-76. PubMed ID: 9171996 [TBL] [Abstract][Full Text] [Related]
72. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227 [TBL] [Abstract][Full Text] [Related]
73. [Localization of point mutations in the coding part of the VHL gene in clear cell renal cancer]. Mikhaĭlenko DS; Grigor'eva MV; Rusakov IG; Kurynin RV; Popov AM; Peters MV; Matveev VB; Iakovlev ES; Nosov DA; Liubchenko LN; Tiuliandin SA; Strel'nikov VV; Zaletaev DV Mol Biol (Mosk); 2012; 46(1):71-81. PubMed ID: 22642103 [TBL] [Abstract][Full Text] [Related]